{
    "clinical_study": {
        "@rank": "41892", 
        "arm_group": {
            "arm_group_label": "Pregnancy Cases", 
            "description": "Pregnant women exposed to Sanofi Pasteur's Quadrivalent Influenza Vaccine (QIV)"
        }, 
        "brief_summary": {
            "textblock": "The Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry will be a\n      prospectively recruited pregnancy surveillance program designed to collect and analyze\n      information on vaccine exposures, pregnancy outcomes, and fetal and offspring outcomes."
        }, 
        "brief_title": "Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry", 
        "completion_date": {
            "#text": "August 2019", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Pregnancy", 
            "Influenza"
        ], 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "detailed_description": {
            "textblock": "Pregnant women will be enrolled in the registry prospectively (after exposure to QIV in\n      routine clinical settings but before knowledge of the pregnancy outcome). Women exposed to\n      QIV with or without adverse events will be recorded in the Global Pharmacovigilance Database\n      and medically reviewed. Pregnancy outcomes will be sought via questionnaires sent to the\n      reporter at enrollment, estimated time of delivery, and six months after delivery.\n      Descriptive statistical methods will be the primary approach for summarizing data.\n\n      No vaccine products will be provided or administered as part of this registry protocol."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Pregnant women will be enrolled in the registry prospectively (after exposure to\n             Quadrivalent Influenza Vaccine (QIV) but before the conduct of any prenatal tests\n             that could provide knowledge of the outcome of pregnancy). If the condition of the\n             fetus has already been assessed through prenatal testing (e.g., targeted ultrasound,\n             amniocentesis, etc.), such reports will be considered retrospective reports.\n             Retrospective reports are also eligible for the registry but they will be analyzed\n             separately from prospective reports.\n\n        Exclusion Criteria:\n\n          -  N/A"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Pregnant women exposed to Sanofi Pasteur's Quadrivalent Influenza Vaccine (QIV)"
            }
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01945424", 
            "org_study_id": "QIV08", 
            "secondary_id": "U1111-1143-8433"
        }, 
        "intervention": {
            "arm_group_label": "Pregnancy Cases", 
            "description": "No Intervention as part of this protocol", 
            "intervention_name": "Quadrivalent Influenza Vaccine (QIV)", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Quadrivalent Influenza Vaccine", 
            "Pregnancy Registry", 
            "Influenza"
        ], 
        "lastchanged_date": "March 18, 2014", 
        "link": [
            {
                "url": "http://www.sanofipasteur.com"
            }, 
            {
                "url": "http://www.sanofi.com"
            }, 
            {
                "url": "http://www.sanofipasteurpregnancyregistry.com/"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Albany", 
                        "country": "United States", 
                        "state": "New York"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Harrisburg", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Sanofi Pasteur Quadrivalent Influenza Vaccine Pregnancy Registry Protocol", 
        "overall_contact": {
            "email": "RegistryContactUs@sanofipasteur.com", 
            "last_name": "Public Registry Sanofi Pasteur"
        }, 
        "overall_official": {
            "affiliation": "Sanofi Pasteur Inc.", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Data will be summarized using descriptive statistical methods and stratified by pregnancy outcome (spontaneous abortion, elective termination, fetal death/stillbirth, live birth) and timing of vaccine exposure. Infant outcomes include birth defects and physical and social development.", 
            "measure": "Number of cases and outcomes of pregnancies following exposure to QIV vaccine", 
            "safety_issue": "No", 
            "time_frame": "Up to six years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01945424"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sanofi Pasteur, a Sanofi Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "15 Months", 
        "verification_date": "March 2014"
    }
}